Evaluation of Patient Transmission Factor Following the Administration of 177Lu-DOTATATE

177Lu-DOTATATE is a radionuclide therapy that is FDA approved for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. Treatment facilities are required to determine the maximum radiation dose from such subjects to the maximally exposed member of the public,...

Full description

Saved in:

Bibliographic Details
Published in:	Health physics (1958) Vol. 123; no. 6; pp. 457 - 463
Main Authors:	Recca, Kimyli, Muneeb, Aeman, Helstern, Christopher, Lemieux, Bryan, Das, Satya, Jessop, Aaron
Format:	Journal Article
Language:	English
Published:	United States Lippincott Williams & Wilkins 01-12-2022 Lippincott Williams & Wilkins Ovid Technologies
Subjects:	Dosimetry Federal regulation Lutetium isotopes Neuroendocrine tumors Nuclear medicine Radiation Radiation dosage Radiation therapy Radioisotopes Somatostatin Tumors
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	177Lu-DOTATATE is a radionuclide therapy that is FDA approved for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. Treatment facilities are required to determine the maximum radiation dose from such subjects to the maximally exposed member of the public, ensuring that the total effective dose equivalent (TEDE) does not exceed regulatory limits. If the calculated TEDE meets the regulatory limits, the patient is eligible for release and provided instructions with radiation precautions. This study aims to determine a mean transmission factor to the patient to improve accuracy and individualize the estimation of the TEDE.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	0017-9078 1538-5159
DOI:	10.1097/HP.0000000000001611